What happened to TransEnterix?
TransEnterix (NYSEARCA:TRXC), which is a medical devices company, announced this week that it will change its corporate name to Asensus Surgical, but there’s no telling how much that will matter to TRXC stock in the long term.
Does TransEnterix have a future?
TransEnterix has projected its cash runway to last until the end of 2022. There are also many regulatory catalysts anticipated in the first half of 2020 that can further push up share prices. TransEnterix is expecting the FDA’s clearance for use of the Senhance system in general surgery indication.
Who is the leader in robotic surgery?
Intuitive Surgical held the leading position in the United States robotic surgery market in 2018. Intuitive received FDA approval for their first-ever da Vinci® robotic system in 2000, and since then, they have expanded on the da Vinci® system to yield a robotic surgery empire.
Who makes the Davinci surgical robot?
Intuitive Surgical Inc.
The da Vinci Surgical System was approved by the U.S. Food and Drug Administration (FDA) in 2000. Intuitive Surgical Inc., headquartered in Sunnyvale, California, is responsible for the manufacturing and marketing of the computer-assisted robotic surgical tool.
Who owns ascensus surgical?
History and ownership In 2015, Ascensus was offered for sale by private equity investment firm JC Flowers. In the fourth quarter of 2015, the company was acquired by Genstar Capital and Aquiline Capital Partners.
Why did TransEnterix change their name?
TransEnterix has changed its corporate name to Asensus Surgical, reflecting the firm’s vision to shape surgery’s future by integrating computer vision and machine learning with surgical robotics.
Is TRXC stock a buy?
TransEnterix currently has a Zacks Rank of #2 (Buy). Our research shows that stocks rated Zacks Rank #1 (Strong Buy) and #2 (Buy) and Style Scores of A or B outperform the market over the following one-month period.
Is TRXC FDA approved?
Asensus Surgical announces FDA clearance for Senhance Surgical System. Asensus Surgical, formerly TransEnterix, Inc. (NYSEMKT:TRXC) has announced that the company received an additional FDA clearance for the Senhance Surgical System sending TransEnterix shares ~28.1% higher in the pre-market.
Who are Isrg competitors?
The main competitors of Intuitive Surgical include Abbott Laboratories (ABT), Medtronic (MDT), Stryker (SYK), Edwards Lifesciences (EW), Becton, Dickinson and (BDX), Boston Scientific (BSX), DexCom (DXCM), IDEXX Laboratories (IDXX), Baxter International (BAX), and ResMed (RMD).
Who makes robots for hospitals?
Intuitive Surgical (NSDQ:ISRG) pioneered robotic surgery through the early 2000s and remains the dominant player, but major companies including Medtronic (NYSE:MDT) and Johnson & Johnson (NYSE:JNJ) have big plans to enter the space and compete.
What is transtransenterix’s forecast for the robotic surgery market?
TransEnterix highlights the large and fast-growing market for surgical robotics with laparoscopic robotic surgery representing a significant greenfield opportunity. The company estimates that the $3.7 billion abdominal robotic surgery market in 2018 may grow by over 4x through 2023 to $16 billion.
Is transenterix plc (TRX) profitable?
While TransEnterix is not expected to be profitable over the period, the expectation is that losses narrow going forward benefiting from top-line growth as the business scales. TransEnterix came to our attention given the exceptional momentum shares have presented in recent months.
What is transtransenterix (trxC)?
TransEnterix ( TRXC) is a medical devices company developing a surgical robotic platform for Laparoscopy, which are minimally invasive operations on the abdomen and pelvic region. Its “Senhance” system uses a digital interface with augmented intelligence and machine vision to assist trained surgeons.
How big is the abdominal robotic surgery market?
The company estimates that the $3.7 billion abdominal robotic surgery market in 2018 may grow by over 4x through 2023 to $16 billion. Between the 10 million abdominal surgical procedures performed in the U.S. and Europe each year, 4 million are “open surgeries” which are based on a traditional large scalpel incision.